Publications by authors named "Trisha Piontek"
Article Synopsis
- - In the DREAMM-2 study, belantamab mafodotin showed significant effectiveness and a manageable safety profile for patients with relapsed/refractory multiple myeloma (RRMM), particularly those who had failed multiple previous treatments.
- - Patient-reported outcomes (PROs) indicated that while some patients experienced ocular symptoms (like difficulties with vision, driving, and reading), these symptoms improved over time with recovery times ranging from 23.5 to 44 days.
- - Overall health-related quality of life (HRQOL) and core symptoms of multiple myeloma, including fatigue and pain, were maintained during treatment, supporting the use of belantamab mafodotin in RRMM patients and suggesting potential for
Background: On the basis of the DREAMM-2 study (ClinicalTrials.gov identifier NCT03525678), single-agent belantamab mafodotin (belamaf) was approved for patients with relapsed or refractory multiple myeloma (RRMM) who received ≥4 prior therapies, including anti-CD38 therapy. The authors investigated longer term efficacy and safety outcomes in DREAMM-2 after 13 months of follow-up among patients who received belamaf 2.
View Article and Find Full Text PDFArticle Synopsis
- * The need for management guidelines was identified due to the novel corneal events arising from the treatment, leading to recommendations for collaboration between hematology/oncology professionals and eye care specialists.
- * Key guidelines include regular eye exams for patients on belamaf, assessing corneal event severity, and using findings to guide treatment decisions, aiming to reduce ocular risks while maintaining treatment benefits.
DREAMM-2 (NCT03525678) is an ongoing global, open-label, phase 2 study of single-agent belantamab mafodotin (belamaf; GSK2857916), a B-cell maturation antigen-targeting antibody-drug conjugate, in a frozen-liquid presentation in patients with relapsed/refractory multiple myeloma (RRMM). Alongside the main study, following identical inclusion/exclusion criteria, a separate patient cohort was enrolled to receive belamaf in a lyophilised presentation (3.4 mg/kg, every 3 weeks) until disease progression/unacceptable toxicity.
View Article and Find Full Text PDFArticle Synopsis
- The authors emphasize the need to correct information in their previous article based on new FDA guidelines.
- These corrections focus specifically on the drug belantamab Mafodotin (belamaf).
- Recent changes to the FDA label impact how belamaf should be used and understood in clinical settings.
Introduction: Patients with relapsed or refractory multiple myeloma (RRMM) represent an unmet clinical need. Belantamab mafodotin (belamaf; GSK2857916) is a first-in-class antibody-drug conjugate (ADC; or immunoconjugate) that delivers a cytotoxic payload, monomethyl auristatin F (MMAF), to myeloma cells. In the phase II DREAMM-2 study (NCT03525678), single-agent belamaf (2.
View Article and Find Full Text PDFBackground: Belantamab mafodotin (GSK2857916), an immunoconjugate targeting B-cell maturation antigen, showed single-agent activity in the phase 1 DREAMM-1 study in heavily pre-treated patients with relapsed or refractory multiple myeloma. We further investigated the safety and activity of belantamab mafodotin in the DREAMM-2 study.
Methods: DREAMM-2 is an open-label, two-arm, phase 2 study done at 58 multiple myeloma specialty centres in eight countries.